Compare ALLT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | IVVD |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.6M | 437.1M |
| IPO Year | 2006 | 2021 |
| Metric | ALLT | IVVD |
|---|---|---|
| Price | $7.07 | $1.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $12.40 | $8.75 |
| AVG Volume (30 Days) | 344.2K | ★ 2.6M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $15.84 | $147.67 |
| Revenue Next Year | $12.08 | $22.76 |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $4.37 | $0.46 |
| 52 Week High | $11.92 | $3.07 |
| Indicator | ALLT | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 37.30 |
| Support Level | $6.20 | $0.69 |
| Resistance Level | $8.20 | $1.41 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 100.00 | 16.28 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.